Regular ArticleUsefulness of Immunohistochemical Staining for p53 in the Prognosis of Breast Carcinomas: Correlations with Established Prognosis Parameters and with the Proliferation Marker, MIB-1
References (0)
Cited by (53)
Breast Cancer Biomarkers
2005, Advances in Clinical ChemistryCitation Excerpt :In general, breast carcinomas with p53 mutations are associated with high histologic grade, high mitotic index, high cell proliferation rate, aneuploid DNA content, negative assays for estrogen and progesterone receptor [46], and variable association with amplification of oncogenes such as HER‐2/neu, C‐myc, ras, and int‐2 [47]. Some (but not all) studies have implicated p53 mutation with resistance to hormonal, adjuvant, and neo‐adjuvant chemotherapy and combination chemotherapy for metastatic disease encompassing a variety of agents, including anthracyclines and taxanes [48–56]. Currently, determination of p53 status is not included as a part of the standard of practice for the management of breast cancer.
Positron emission tomography imaging of cell proliferation in oncology
2004, Clinical OncologyStreptomyces Levis ABRIINW111 inhibits SW480 cells growth by apoptosis induction
2018, Advanced Pharmaceutical BulletinIdentification of therapeutic targets of breast cancer
2016, International Journal of Clinical and Experimental MedicineBreast cancer statistics and markers
2014, Journal of Cancer Research and Therapeutics
Copyright © 1995 Academic Press. All rights reserved.